Epigenetics: an emerging target class for drug screening. Spring 11By Dr John Comley Heightened awareness of the potential importance of epigenetic targets in many disease areas, and growing vendor interest in developing new assays to screen DNA methylation and histone mo...
|
Moving forward with label-free technology. Winter 10By Dr Jennifer Hartigan, Cindy Liu and William Downey Label-free technology is gaining acceptance and opening doors for new drug discovery. Relatively new in the well-established world of high throughput screening (HTS), label-free technolog...
|
HTS Systems: impact of reliability on downtime and drug discovery. Winter 10By Dr John Comley This article reports the results of a survey on the reliability of automated HTS assay systems and the effect of reliability on output. Evidence supporting the view that HTS systems have ...
|
Current trends in label-free technologies. Fall 10By Philip Rawlins Drug Discovery Label-free technologies have been used throughout drug discovery for the detection and characterisation of molecular interactions. The implementation of automated systems, increased sensi...
|
The industrial evolution of screening infrastructure industrialisation of screening depends upon the use of a stable,mature infrastructure. Fall 03By Chris Molloy According to a recent Boston Consulting Group report, a pharmaceutical company needs to spend 900 million ($810 million) on R&D to bring a product to market.This is almost three times th...
|
Fluorescence Lifetime: finally picking up momentum! Summer 10By Dr John Comley Fluorescence lifetime (FLT) largely failed to make a significant inroad as a screening technology when it was first introduced nearly a decade ago, despite the fact that intrinsically it ...
|
|
|
